Di seguito l'elenco completo dei nostri comunicati stampa (pagina 2 di 28):
Emcure Pharmaceutical's IPO raises Rs 1,952 crore, subscribed 67.87 times. Backed by Bain Capital, priced Rs 960-1,008 per share for Rs 19,060 crore valuation.
Pulsus Group, led by CEO Dr. Srinubabu Gedela, announces a Rs 300 crore AI-driven pharma healthcare IT hub in Ameenpur, Telangana.
GSK plc and Medicines for Malaria Venture introduce a groundbreaking single-dose medication, tafenoquine, to prevent Plasmodium vivax malaria recurrence.
Recce Pharmaceuticals' R327 shows promising results, achieving over 99.99999% reduction in superbug Acinetobacter baumannii, outperforming ciprofloxacin.
Yuhan Corp. and ProGen announce R&D collaboration to develop innovative drugs for obesity and diabetes using bispecific antibody platform.
Ascentage Pharma's olverembatinib approved in Macau for treating resistant CML, expanding regional reach and collaborations.
Valeant ups Salix bid to $10.96B, outbidding Endo in major cash deal, marking its largest acquisition with financial and strategic implications.
Myricx Bio, a UK-based biotech firm, secured £90M to expand its NMT inhibitor ADC platform, backed by Novo Holdings, Abingworth, and other key investors.
Novartis, Pfizer, Otsuka, and Novo Nordisk reprimanded by PMCPA for ABPI code breaches. Novo Nordisk faces public reprimand over £7.8M.
Lotte Biologics breaks ground on its first plant in Incheon, marking a 4.6 trillion won investment and a significant step in Korea's biotech industry.
Aptamer Group plc collaborates with AstraZeneca to enhance siRNA delivery using Optimer binders, targeting fibrotic liver cells for innovative gene therapies.
Biostar Pharma's Utidelone Injection gets FDA approval for a Phase 2 study targeting HER2- breast cancer brain metastasis.
Körber partners with Anrate Biopharmaceutical to enhance operations with advanced manufacturing solutions for a smart factory in China's biopharma sector.
MedPharm merges with Tergus Pharma to form a CDMO, enhancing drug development and manufacturing services globally. Majority owned by Ampersand Capital Partners.
IASO Bio acquires global rights to FUCASO® from Innovent Biologics, expanding its cell therapy portfolio for treating multiple myeloma and autoimmune diseases.
Roche announces the re-release of Susvimo® for intravitreal use in the US, offering a new ocular implant for neovascular AMD treatment, following FDA approval.
ORLADEYO® approved by DIGEMID in Peru for preventing hereditary angioedema attacks in adults and children aged 12+, a milestone in treatment options.
Emergent BioSolutions to receive $50M from Johnson & Johnson to settle COVID-19 vaccine production dispute, ending a problematic collaboration.
Discover YARAL Pharma, supplying exclusive gel-cap levothyroxine sodium for hypothyroidism treatment in the U.S., made for absorption & allergen-free benefits.
Discover Shilpa Pharma Lifesciences, Raichur, Karnataka. Awarded ANVISA GMP Certification for oncology and non-oncology APIs, ensuring global quality standards.
Alembic Pharmaceuticals secures USFDA approval for its generic Bromfenac Ophthalmic Solution, boosting its ANDA approvals to 207 with a market size of $168M.
Reviva Pharmaceuticals secures European Patent for brilaroxazine to treat pulmonary hypertension, expanding their CNS and cardiometabolic treatment portfolio.
XyloCor Therapeutics teams with SmartWise to advance gene therapy for refractory angina using the innovative Extroducer® Catheter System®.
OKYO Pharma pioneers therapies for dry eye disease and neuropathic corneal pain, unveiling Phase 2 trial insights on key symptom endpoints.
Elevar Therapeutics announces intention to resubmit NDA for rivoceranib and camrelizumab, advancing treatment for Unresectable Hepatocellular Carcinoma.
Thermo Fisher Scientific finalizes $3.1B acquisition of Olink Holding AB, enhancing its proteomics solutions and expanding capabilities in life sciences.
Evotec SE and Pfizer announce a multi-year research collaboration targeting metabolic and infectious diseases.
Novo Nordisk and Bio Farma partner to enhance insulin packaging in Indonesia, combining Novo's diabetes care expertise with Bio Farma's local infrastructure.
Pfizer selects preferred once-daily formulation for danuglipron, advancing in obesity treatment. Study shows promising pharmacokinetics and safety profile.
MedPharm, Ltd. and Tergus Pharma merge to form a leading CDMO specializing in topical and transepithelial products, led by CEO Michael Kane.
Novo Nordisk receives FDA Complete Response Letter for once-weekly basal insulin icodec, addressing manufacturing and type 1 diabetes indication concerns.
Sichuan Biokin Pharmaceutical Co. aims to raise $500M through a Hong Kong IPO, with Goldman Sachs, JPMorgan, and Citic as joint sponsors
Algernon Pharmaceuticals announces a non-brokered private placement to raise $250,000 via units priced at $0.12 each, closing July 20, 2024.
Merz Therapeutics boosts its neurology portfolio by acquiring INBRIJA® and AMPYRA®, enhancing treatments for Parkinson's disease and entering the MS market.
FDA raids in Vasai reveal illegal drug manufacturing by Gaharwar Pharma, seizing items worth Rs. 1.41 crore; investigation ongoing.
AbbVie submits applications to FDA and EMA for upadacitinib approval to treat adult patients with giant cell arteritis.
Merck acquires EyeBio, enhancing its pipeline with Restoret™ for retinal diseases, entering pivotal trials in 2024.
Alembic receives USFDA tentative approval for Selexipag Injection, 1,800 mcg/vial, treating PAH to delay disease progression.
Federal court dismisses Boehringer Ingelheim's challenge to Medicare Drug Price Negotiation, upholding Biden administration's policy.
Senate passes Affordable Prescriptions for Patients Act to limit patent barriers, boosting biosimilars and generics.
USFDA inspection clears Piramal Pharma's Ahmedabad site, boosting FDA-approved clinical and commercial batch services.
Curi RMB and Oasis challenge Taisho Pharma buyout in court, arguing the tender offer undervalues the shares.
Moderna and Mitsubishi Tanabe partner to co-promote mRNA respiratory vaccines, including Spikevax, in Japan till 2029.
Daewoong Pharmaceutical's Nabota, now approved in Argentina as Clodew, is the first Korean BTX product to enter the market, set for Q4 launch.
Recce Pharmaceuticals Ltd received a $2M grant from the U.S. Dept. of Defense to develop RECCE 327 Gel for treating military burn wound infections.
Medicus Pharma updates FDA with non-invasive basal cell carcinoma treatment using doxorubicin micro-needle arrays in Phase 2 protocol submission.
MIRA Pharmaceuticals, Inc. reports preclinical results for MIRA-55, an innovative oral marijuana analog, showing potential to treat anxiety & cognitive decline.
GC Cell and Checkpoint Therapeutics unite to synergize cosibelimab and Immuncell-LC in groundbreaking cancer therapies.
Heron Therapeutics celebrates CMS's 2025 Non-Opioid Policy inclusion of ZYNRELEF® for post-surgery pain relief, aiming to reduce opioid use.
Lupin sells US women's health business to Evofem Biosciences, focusing on respiratory and neurological diseases.
India tightens Schedule G drug ad rules to curb misleading promotions. Public feedback invited on draft changes to the Drugs and Cosmetics Rules, 1945.
Silo Pharma acquires exclusive global license for SPC-14, targeting Alzheimer's, leveraging FDA's 505(b)(2) pathway.
Legend Biotech, known for its CAR-T therapy, evaluates takeover bid; J&J speculated as potential acquirer.
Emmaus Life Sciences achieves FDA compliance success, ensuring drug safety and quality with top inspection results.
Supreme Court supports NPPA's recovery of Rs 4.65 crore from Sun Pharma for violating DPCO pricing on Roscilox.
Sumitomo Pharma's DSP-5336, targeting AML with KMT2A rearrangement or NPM1 mutation, earns FDA Fast Track with strong clinical results.
FDA rejection of Hengrui's camrelizumab cites facility issues; resubmission planned, reinspection needed for approval.
SPI Pharma and Inimmune team up to create and commercialize innovative adjuvant systems, enhancing vaccine efficacy.
OMERS acquires Aclaris's future royalty payments from Lilly's OLUMIANT sales for alopecia areata, paying $26.5M.
Johnson & Johnson to pay $505M to settle disputes with talc suppliers, resolving ongoing conflicts amid talc cancer lawsuits.
Genomics plc and Vertex Pharmaceuticals renew collaboration for three more years, leveraging human genetics and AI to advance precise healthcare solutions.
Kindeva Drug Delivery's Woodbury, MN facility achieves FDA VAI status, ensuring top-tier analytical services for pharmaceuticals and medical devices.
Sionna Therapeutics acquires global rights from AbbVie to develop cystic fibrosis treatments galicaftor, navocaftor, and ABBV-2851, advancing CF care.
Upperton Pharma Solutions secures MHRA approval for a new 50,000 sq ft GMP facility in Nottingham, enhancing oral, nasal, and pulmonary drug production.
The FDA warns Cadila Pharmaceuticals Ltd for CGMP lapses at its Ankleshwar plant, risking US export license. Urgent corrective measures required within 15 days.
ICER warns Verona Pharma's $2,950/month COPD drug Ohtuvayre may face access barriers due to high cost.
Corden Pharma invests €900M to enhance peptide production capacity, addressing diabetic drug shortages.
Glenmark gains FDA approval for Topiramate Capsules, enhancing its US portfolio with Janssen's Topamax® equivalents.
Seers' mobiCARE, a 19g device, offers 9-day ECG monitoring, improving early heart disease detection using AI.
Zensar Technologies acquires BridgeView Lifesciences for $25M, boosting healthcare and life sciences offerings.
Sanofi plans €400M investment in Hyderabad, India, increasing its global capacity centre workforce to 2,600.
GC Biopharma sells Hong Kong subsidiary to CR Pharmaceutical for 350B won, boosting financial stability and exports.
Kintor pivots to cosmetic market with KX-826 hair loss treatment after clinical trial failures to boost revenue.
Endo USA recalls clonazepam tablets due to labeling error. Cartons incorrectly state 0.125mg instead of 0.25mg, though blister packs are correct.
Acurx Pharmaceuticals secures a new patent for ibezapolstat, targeting C. difficile infection, enhancing gut health, with Phase 3 trials upcoming.
Dermata Therapeutics reaches halfway in Phase 3 trial for DMT310, a once-weekly acne treatment. Topline data expected Q1 2025.
Scorpius Holdings Inc. completes initial cGMP microbial batches at San Antonio, marking a pivotal step in clinical manufacturing with strong client interest.
Phathom’s VOQUEZNA gains FDA approval for Non-Erosive GERD, offering novel 24-hour heartburn relief.
Med journal publishes LILAC studies showing DAYBUE improves Rett syndrome symptoms with a consistent safety profile.
Silo Pharma and Resyca BV partner on nasal spray tech for SPC-15, enhancing brain delivery for PTSD treatment.
Zuellig Pharma & Institut AllergoSan Forge Decade-Long Partnership to Boost Probiotic Brand OMNi-BiOTiC® in Asia's Growing Market.
Teva’s Phase 3 SPACE study shows AJOVY (fremanezumab) effectively prevents migraines in kids and teens, with a safe profile and no new concerns.
GSK's Blenrep MAA for relapsed/refractory multiple myeloma, combined with BorDex or PomDex, is accepted by EMA. CHMP review underway for potential approval.
Jonjo O'Neill Racing has secured a sponsorship deal with Wasdell Group, Europe's largest independent contract packer and a rising star in pharma manufacturing.
Daewoong Bio banned from China's VBP due to manufacturing errors; cefodizime sodium supply affected.
60 Degrees Pharmaceuticals Begins Clinical Trials for Tafenoquine to Treat Babesiosis in Partnership with Top Medical Centers.
Capra Biosciences wins $7.5M project to scale U.S. biomanufacturing of APIs, enhancing domestic production and addressing supply chain issues.
SemaPhore™ nanoparticles deliver SOD2 mRNA to treat AAA, lowering aortic dilation, rupture risk, and boosting survival.
Shuttle Pharma's HDAC inhibitor SP-1-303 shows potential in inhibiting estrogen receptor positive breast cancer growth.
EMA validates Opdivo + Yervoy as first-line treatment for advanced HCC, with significant OS improvement in CheckMate -9DW trial.
Athenahealth completes UDS+ synthetic testing, enhancing FQHC support with streamlined data submission and improved patient outcomes via advanced technology.
LEO Pharma’s delgocitinib cream trial results featured in The Lancet, marking a milestone for new treatments in chronic hand eczema.
Boehringer Ingelheim launches a Humira biosimilar at 92% off, priced at $550 via GoodRx, aiming to boost access and market share.
EMA accepts Ono Pharma's MAA for vimseltinib to treat TGCT, following $2.4B Deciphera acquisition, eyeing $1B sales.
Medicamen Organics partners with Depot Pharmacy Yego, investing $75K to launch operations in Rwanda, leveraging Kigali's strategic location and tax benefits.
Ayesha T. Haq calls for policy reforms to address regulatory and economic barriers for pharma MNCs in Pakistan.
Lupin's U.S. partner, ForDoz Pharma, secures FDA approval for generic Doxorubicin Hydrochloride Liposome Injection, targeting ovarian cancer and more.
TME Pharma Unveils Strategy to Outsource and Capitalize on NOX-E36 for Ophthalmic Diseases, Citing Strong Clinical Potential and Market Opportunity.
Addex Therapeutics confirms Janssen halts ADX71149 epilepsy development after Phase 2 results but will continue data analysis and collaboration efforts.
Meitheal Pharmaceuticals acquires North American rights to CONTEPO for drug-resistant UTIs, with FDA decision expected in 2024.
Traws Pharma appoints KPMG LLP as its new independent accounting firm, effective December 2024, after no disputes with previous auditor Ernst & Young.
STADA and Alvotech launch Uzpruvo® in Europe, the first Stelara® biosimilar, enhancing access for Crohn's disease and psoriasis patients.
Tobinco’s Lufart wins Best Pharmaceutical Product at Ghana International Products Event, showcasing local innovation in healthcare.
RADIAN to fund HIV initiatives in EECA, extending aid to Ukrainian refugees, improving access to vital services.
Chugai transfers MONILAC Syrup rights to Maruishi, including manufacturing and marketing permissions, to optimize the product's value.
MIRA's Ketamir-2, a novel oral ketamine analogue, shows potential for treating neurological conditions with enhanced absorption.
Aligos and Amoytop partner on a Phase 1b trial to evaluate ALG-000184 and PEGBING® for chronic hepatitis B treatment.
SynaptixBio extends collaboration with Evotec to develop new ASO drug candidates for TUBB4A leukodystrophy treatment.
Agilent Technologies to acquire BIOVECTRA for $925M, expanding capabilities in biologics and accelerating drug development. Deal expected to close before 2025.
Kobayashi Pharmaceutical’s chairman and president resign amid scrutiny over red yeast rice supplement linked to health issues and disclosure delays.
Hikma expands acetaminophen injection recall to include consumers due to possible dexmedetomidine mix-up, posing serious health risks.
aTyr Pharma completes Phase 3 EFZO-FIT™ trial enrollment for efzofitimod in pulmonary sarcoidosis. Results expected in Q3 2025, marking a key milestone.
Cytoki Pharma's CK-0045 demonstrates positive Phase 1 results in reducing obesity and type 2 diabetes markers.
MidEuropa will acquire a majority stake in Famar, a pharmaceutical CDMO, to support its growth and expansion, with the deal expected to close in late 2024.
Mayne Pharma sues Sun Pharma over patent infringement on menopause treatment IMVEXXY, triggering a 30-month FDA stay.
Autobahn Labs and Charles River collaborate to advance early-stage therapeutics, with Charles River joining as an investor.
Scorpius to launch its first cGMP mammalian manufacturing campaign at San Antonio facility in Q3 2024, expanding biopharma.
Alcami expands Garner facility, enhancing storage for vaccines and biopharmaceuticals, and creating new jobs.
Tonix receives $34M from DoD for developing a broad-spectrum antiviral targeting CD45 protein over five years.
FDA expands BioMarin's BRINEURA approval to treat all ages with CLN2 disease, based on new clinical trial data.
FDA doubts AstraZeneca's Imfinzi efficacy and safety for lung cancer, with pivotal trial results and overtreatment risks.
Carbogen Amcis triumphs in FDA inspections, with spotless reports for Neuland and Aarau facilities, reinforcing excellence.
Novo Nordisk is building a $4.1B aseptic production plant in Clayton, NC, adding 1,000 jobs and boosting output by 2029.
Mankind Pharma is in advanced talks to acquire Bharat Serums for $1.5B; deal could be finalized soon.
SPI Pharma's ValensTM brand launches, uniting products for vaccines, biologics, and parenteral dosage forms.
Gland Pharma's Hyderabad site gets 2 procedural observations in surprise US FDA inspection, plans remedies.
Sun Pharma's LEQSELVI gets FDA nod for treating severe alopecia areata in adults, offering new hope.
Cue Biopharma refocuses on autoimmune programs, cutting costs and staff to extend cash runway to mid-2025.
Catalyst partners with Kye Pharmaceuticals to bring AGAMREE, a novel DMD treatment, to the Canadian market.
Summit Therapeutics and MD Anderson join forces for a five-year partnership to develop ivonescimab for cancer.
Windtree updates on istaroxime's clinical progress, with Phase 2 results expected soon and new studies planned.
Biopharma Q2 2024 earnings strong; drug price negotiations under the Inflation Reduction Act progressing with limited impact.
EU rejects Eisai and Biogen's Alzheimer's drug Leqembi due to serious brain swelling risks and limited trial benefits.
Biopharma company delists from OTCQB due to low volume, continues trading on London Stock Exchange's AIM Market.
SFV drum pump provides efficient fluid transmission for various needs, with material choices, connections, and motor options.
FDA authorizes LIVMARLI label expansion for cholestatic pruritus in PFIC patients aged 12 months and older.
JSR Life Sciences' KBI Biopharma extends a $250M manufacturing deal with a global pharma partner, committing to produce two therapeutic products through 2029.
Checkpoint Therapeutics' cosibelimab BLA for cSCC accepted by FDA for review, with a PDUFA goal date of Dec 28, 2024, after resubmission resolves prior concerns
QuVa Pharma acquires LogicStream, integrating predictive analytics to tackle drug shortages and improve pharmacy operations.
Kobayashi Pharmaceutical didn't report certain items to the health ministry; instructed to submit a report by Wednesday.
FDA grants Orphan Drug and Rare Pediatric Disease status to Cellectis' UCART22 for treating Acute Lymphoblastic Leukemia.
Abbott ordered to pay $495M after jury finds specialized formula caused NEC in preterm infants, leading to lawsuit.
A dengue prevention initiative by Takeda and USAID, educating communities in Maharashtra, Odisha, and Uttar Pradesh on disease prevention.
New $20M pharmaceutical plant opens in Kabul, adhering to WHO standards, promoting local manufacturing and reducing imports.
Daewoong's Versiporosin safe in Phase 2 IPF trials; IDMC final review in 2025 for unique collagen inhibitor.
Schrödinger launches a new initiative to enhance its platform for assessing toxicology risks in early drug discovery, backed by a $10M Gates Foundation grant.
Pharmaceutical Society of Kenya opposes a bill to exclude miraa's psychoactive elements from regulation, warning of health risks & international law violations.
Mauritius' antitrust office investigates potential price-fixing by pharmaceutical importers and wholesalers, affecting drug prices.
Novalead Pharma launches Esmolol-based DFU gel post-Indian approval, aims for global market with further trials.
Paratek's Nuzyra, Phase III study for CABP shows safety, efficacy, and non-inferiority to moxifloxacin, paving the way for broader applications.
Fiocruz partners with University of Coimbra to develop radiopharmaceuticals and register medicines in Brazil and Portugal, enhancing tech transfer and public health access.
HLS Therapeutics and Alberta Health finalize PLA for Vascepa reimbursement in cardiovascular disease treatment.
Cyclo Therapeutics receives European patent for Alzheimer's treatment method, effective August 21, 2024, enhancing their patent estate.
Boehringer Ingelheim acquires Nerio Therapeutics up to $1.3B, enhancing its immuno-oncology portfolio with innovative PTPN1/2 inhibitors for cancer treatment.
Eli Lilly launches a powerful Olympic campaign with Team USA, urging everyone to fight for their health and embrace the uniqueness of their bodies.
Calliditas Therapeutics Secures Full EU Marketing Authorization for Kinpeygo, Expanding Treatment Access for IgAN Patients.
Roche acquires LumiraDx's point-of-care tech, enhancing decentralized diagnostics, global healthcare access, and molecular testing.
GSK partners with Flagship Pioneering to develop transformative drugs and vaccines in immunology and respiratory treatments.
Amneal Pharmaceuticals gains FDA approval for potassium phosphates IV bags, simplifying hypophosphatemia treatment ready-to-use, preservative-free injections.
Celldex Therapeutics announces positive topline results from its Phase 2 trial of barzolvolimab, a promising treatment for chronic inducible urticaria.
GSK and Ronald Kimbrow settle lawsuit with GSK denying guilt. Scientific studies find no cancer risk from ranitidine.
Cytiva's Supor Prime filters enhance high-concentration biologic production, lowering blockages and minimizing product loss.
Icure signs with UITC to export Ketoprofen Plaster for joint pain relief. Expands global reach with contracts in Latin America, the U.K., and the UAE.
Waters Corp. launches TA Instruments RS-DSC, a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations.
Genzyme sues Sarepta for infringing viral vector patents, seeks damages and a jury trial over Elevidys production.
Vertex's suzetrigine NDA accepted by FDA, potentially the first new acute pain treatment in 20 years. Priority review, PDUFA date set for Jan 30, 2025.
CinFina Pharma launches Phase 1 MAD trial for CIN-110, a promising PYY3-36 analog, to assess its safety, tolerability, and effectiveness in treating obesity.
Eli Lilly pledges $5,000 per Team USA record/medal to health equality groups, could donate over $1M during Olympics.
CNS Pharmaceuticals announces an exclusive licensing deal for TPI 287 to advance treatments for brain cancer. Join the webcast on July 30 for insights.
NeuroBo Pharmaceuticals has signed an exclusive license with MThera Pharma for NB-01, aimed at treating painful diabetic neuropathy in clinical trials.
Jacobs secures a contract to upgrade Onondaga County's sewer system using innovative management and Digital OneWater solutions.
Botanix's SofdraTM approved by FDA for axillary hyperhidrosis; $70M secured, launch starts Q3 2024 with digital release in Q4.
Telix's TLX250-CDx BLA faces FDA sterility issue; resubmission in 90 days, no change to 2024 forecast.
Celltrion Inc. gains Health Canada approval for its biosimilar Steqeyma, targeting autoimmune diseases, marking its entry into the North American market.
Chugai secures exclusive rights for inavolisib, a PI3K alpha inhibitor for advanced HR-positive, HER2-negative breast cancer, in a deal with Roche.
Adial Pharmaceuticals files a new patent for AD04, aiming to protect its lead treatment for AUD until 2044.
The FDA grants RPDD to Theriva Biologics' VCN-01 for retinoblastoma, enhancing treatment development for this rare cancer.
Tonix Pharmaceuticals highlights NASEM's Long COVID definition linking fibromyalgia to SARS-CoV-2, expanding the market potential for its drug Tonmya.
Contineum Therapeutics' PIPE-307, an M1 receptor antagonist for RRMS, shows positive preclinical data and enters Phase 2 trials.
AbCellera and Lilly expand partnership to develop therapeutic antibodies for immunology, neurology, and cardiovascular diseases.
Sound Pharmaceuticals completes Phase 3 trial for SPI-1005, a groundbreaking treatment for Meniere’s Disease, improving hearing loss and tinnitus.
Johnson & Johnson's DARZALEX FASPRO® gains FDA approval for a new quadruplet therapy, expanding treatment options for newly diagnosed multiple myeloma patients.
CHMP Recommends Approval for Amivantamab with Chemotherapy for Advanced NSCLC, Reduces Disease Progression by 52%.
Medicilon and Hengrui Pharma partner to advance preclinical drug assessments, boosting innovation in China's pharmaceutical sector.
MedPharm and Tergus Pharma merge to enhance CDMO capabilities in topical pharmaceuticals, boosting scientific expertise and production efficiency.
Otsuka Pharmaceutical plans to acquire Jnana Therapeutics for over $1 billion, aiming to enhance its drug pipeline and research capabilities in Boston.
CereMark Pharma and Hall of Fame Health partner for Phase 3 study of Alzheimer's and CTE diagnostic agent.
Jagat Pharma introduces Isotine Eye Gummies to support eye health and combat digital strain for all ages.
Halia Therapeutics and Biolexis use AI to identify a promising treatment targeting NLRP3-driven neuroinflammation for Parkinson’s and neurodegenerative diseases
First patient dosed in Phase 3 trial comparing ifinatamab deruxtecan to standard chemotherapy for relapsed SCLC.
Chugai's Alecensa gets Taiwan TFDA approval for adjuvant treatment in ALK-positive NSCLC post-tumor removal.
Vectura Fertin Pharma and Aurora partner to launch new CBD lozenge on Aurora's Canadian medical cannabis platform for patient feedback.
MilliporeSigma acquires Mirus Bio for $600M, bolstering its viral vector production solutions for gene therapies.
BioIVT partners with Germfree to launch a state-of-the-art cleanroom facility in Winchester, VA, enhancing support for cell and gene therapy.
SMS Pharmaceuticals and Sri Avantika Contractors plan a $200M investment in a pharmaceutical park in Vietnam, aiming for $4-5B in additional investments.
Regeneron’s Eylea sales surged to $304M in Q2, revitalizing its franchise despite competition and FDA delays for linvoseltamab.
Merck explores combining Keytruda with RNA-based vaccines alongside Moderna to enhance melanoma treatment options before the drug's patent expiration in 2030.
Sanofi and Vir sign exclusive deal for masked T-cell engagers to target cancer and infectious diseases.
Calls grow for Gilead to reduce lenacapavir price for HIV prevention, highlighting disparity in global drug access.
Alembic Pharma gets US FDA nod for Nelarabine Injection, used for T-cell leukemia/lymphoma, marking its 211th ANDA approval. Market size: $23M.